Trial Profile
A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Pharmacodynamics; Pharmacogenomic; Registrational
- Acronyms ELIOS
- Sponsors AstraZeneca
- 19 Oct 2023 Status changed from active, no longer recruiting to completed.
- 19 Sep 2023 Planned End Date changed from 1 Oct 2023 to 30 Sep 2023.
- 19 Sep 2023 Planned primary completion date changed from 1 Oct 2023 to 30 Sep 2023.